Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali — Clinical Trial Site

10 Registered trials

3 Currently recruiting

Organisation

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

Location

Latina, Italy

Identifier

ORG-100046246

Address

Via Franco Faggiana 1668, 04100, Italy

Departments

#2831: UOC Cardiologia Universitaria
Ambulatorio Cefalee, I.C.O.T.
Cardiology
medico-surgical Sciences and Biotechnologies
N/A
NA
Surgery and Urology
UOC Cardiologia
Urology

Clinical trials at this site (10)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascu… Pending

2025-522486-29-01 Diabetes Mellitus 5
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Surgical treatment with or without apalutamide in subjects with high risk prostate cancer who are candidates for radical prostatectomy and s… Recruiting

2024-515049-41-00 metastatic prostate cancer 4 2024-07-12
FI-3, Fidelia Recruiting

2024-518243-38-00 Fecal incontinence in female and male patients 5 2022-04-20
AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI… Ended

2023-505601-16-00 Chronic Migraine 5 2025-04-22
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04